Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGT9486 Monotherapy and Combination in Advanced Solid Tumors and GIST
NCT02401815Phase 2Completed
- Sponsor
- Cogent Biosciences
- Start
- Mar 2015
- Primary completion
- May 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bezuclastinib in gastrointestinal stromal tumor (GIST), solid tumor, sponsored by Cogent Biosciences. Started Mar 2015; status: completed.
02
Drugs
bezuclastinib
03
Conditions
gastrointestinal stromal tumor (GIST)solid tumor
Beyond the preview
Go deeper on NCT02401815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02401815.